Pluri Inc.
Biotechnology firm with 3D cell-expansion tech for manufacturing cell-based products.
PLUR | TA
Overview
Corporate Details
- ISIN(s):
- US72942G2030
- LEI:
- Country:
- Israel
- Address:
- Park Building No. 5, 3508409 Haifa
- Website:
- https://pluri-biotech.com/
- Sector:
- Manufacturing
Description
Pluri Inc. is a biotechnology company specializing in proprietary 3D cell-expansion technology. The company develops and operates platforms for the scalable, consistent, and cost-effective manufacturing of cell-based products. Its technology is applied across multiple sectors, including regenerative medicine, cell therapy, food technology, and agriculture technology (AgTech). Pluri aims to create next-generation cell-based products to improve human wellbeing and establishes partnerships to leverage its platform. The company also provides Contract Development and Manufacturing Organization (CDMO) services.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-18 16:07 |
8K-nitial interim results from its Phase I study evaluating PLX-R18 as a treatm…
|
English | 36.0 KB | ||
| 2020-11-18 15:01 |
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 De…
|
English | 221.5 KB | ||
| 2020-11-18 15:01 |
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 De…
|
English | 35.9 KB | ||
| 2020-11-06 00:17 |
Form 10-Q For the quarterly period ended September 30, 2020
|
English | 442.2 KB | ||
| 2020-11-06 00:17 |
Form 10-Q For the quarterly period ended September 30, 2020
|
English | 36.2 KB | ||
| 2020-10-20 15:59 |
World Experts in Infectious Diseases & Critical Care Form
Pluristem’s COVID-19…
|
English | 88.9 KB | ||
| 2020-10-20 15:59 |
World Experts in Infectious Diseases & Critical Care Form
Pluristem’s COVID-19…
|
English | 35.9 KB | ||
| 2020-10-13 15:58 |
Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led …
|
English | 90.0 KB | ||
| 2020-10-13 15:58 |
Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led …
|
English | 36.0 KB | ||
| 2020-10-08 11:09 |
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
|
English | 129.4 KB | ||
| 2020-10-08 11:09 |
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
|
English | 35.9 KB | ||
| 2020-10-07 11:00 |
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
|
English | 74.4 KB | ||
| 2020-10-07 11:00 |
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
|
English | 35.9 KB | ||
| 2020-10-01 12:00 |
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint
Projects at Malta Confe…
|
English | 126.6 KB | ||
| 2020-10-01 12:00 |
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint
Projects at Malta Confe…
|
English | 36.0 KB |
Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pluri Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pluri Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
